Edward Tung, legal counsel for Hong Kong-based venture capital firm ORI Capital, discusses the growing importance of ESG, the rise of special purpose acquisition companies (SPACs) and the advantage of having scientific expertise when representing healthcare and biotechnology companies.
Ting Wu of Haiwen & Partners raises some questions to highlight how China's newly implemented drug patent linkage system attempts to resolve drug patent disputes in the early stages, which will have a sweeping impact on market entry strategies for chemical drugs in China
Several major Chinese law firms have set up new offices in Hainan since 2018
The expansion of competing U.S.-China sanctions requirements are forcing multinationals to rethink their traditional global compliance strategies
Andrew Sim and Alanna Rennie of Baker McKenzie discuss the key provisions of the new Judicial Interpretation on plant variety rights (PVR), which will encourage more consistent rulings by the people's court and grant stronger judicial protection to PVR holders in China
PRC companies wanting to list outside China face extended cybersecurity reviews and potentially burdensome documentation submission requirements
Beilei Hou and Zi Ling of King & Wood Mallesons look at the emerging carbon emissions trading scheme in China, and consider the outlook for market access to foreign investors
First high-profile cybersecurity reviews indicate that overseas-listed Chinese tech firms are prime targets for new cybersecurity regime
Rongwei (Ron) Cai, Jianwei (Jerry) Fang, and Dianmeng Zhu of Zhong Lun Law Firm introduce the newly enacted PRC Data Security Law, highlight the core data security protection obligations imposed on companies, and set out steps companies should be taking immediately in order to ensure compliance
New China asset management rules tighten requirements on the due diligence of distributors
